Rita Wesley Driggers, MD

Dr. Susan Scott is a thoracic medical oncologist with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital and Assistant Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Scott has expertise in thoracic malignancies, including non-small cell lung cancer, small cell lung cancer and pulmonary carcinoid tumors, as well as thymic malignancies. She leads the EGFR and HER2 lung cancer research program for Johns Hopkins. Dr. Scott received her undergraduate education at the University of Oxford, UK and medical doctorate from Yale University. She completed residency at the Cleveland Clinic where she also served as Chief Resident in Internal Medicine. Dr. Scott joined Johns Hopkins Oncology for fellowship training in Baltimore and was recruited to the thoracic oncology program to continue work as a physician and clinical scientist focused in lung cancer. Dr. Scott and her team are committed to providing compassionate and individualized care to their patients, including state-of-the-art therapies and clinical trials. Her research interests include clinical trials in resectable lung cancer, innovative applications of immunotherapy, and novel targeted therapies, especially EGFR- and HER2-mutated lung cancers. Dr. Scott is a member of the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and the International Association for the Study of Lung Cancer (IASLC).

Dr. Solmaz Sahebjam is a medical oncologist and an associate professor of oncology at Johns Hopkins University School of Medicine. Her expertise is in primary and metastatic brain tumors, breast cancer, and the development of new drugs for cancer.She earned her medical degree from Iran University of Medical Sciences, followed by a post-doctoral research fellowship at Shriners Hospital, McGill University in Montreal. Dr. Sahebjam completed residency training in internal medicine at Saint Vincent Hospital, followed by a fellowship in internal medicine at the University of Ottawa in Canada. She continued her training with a residency in medical oncology at McGill University in Canada followed by a fellowship in early-phase drug development, breast oncology, and neurooncology at Princess Margaret Hospital, University of Toronto in Canada.Dr. Sahebjam’s research is focused on the development of novel therapeutic regimens for the treatment of cancer including breast and central nervous system malignancies. Over the years, she has led and contributed to numerous clinical trials some of which have resulted in new treatment options for patients with cancer.

Mark J. Levis, M.D., Ph.D., professor of oncology, medicine and pharmacology in the Division of Hematologic Malignancies at the Johns Hopkins University School of Medicine, co-directs the Hematologic Malignancies and Bone Marrow Transplantation Program and directs the Adult Leukemia Service at the Johns Hopkins Sidney Kimmel Cancer Center. In addition to his role within the Kimmel Cancer Center, he serves on the faculty for the Johns Hopkins Graduate Training Program in Cellular and Molecular Medicine, a Ph.D. program that prepares scientists to conduct laboratory research at the cellular and molecular level that is designed to have a direct impact on the understanding of human diseases.Dr. Levis has expertise in acute and chronic myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes.Dr. Levis received his medical degree at the University of California, San Francisco School of Medicine, where he also earned his Ph.D. in Biochemistry. He completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology.Dr. Levis is a member of the American Society of Hematology, the American Society of Clinical Oncology and the European Hematology Association. He is an ad hoc member of the Oncology Drug Advisory Committee, as well as an ad hoc manuscript referee for peer-reviewed journals such as New England Journal of Medicine; Leukemia; Clinical Cancer Research; and The American Journal of Hematology.Dr. Levis has earned numerous awards, such as the Daniel Nathans Research Award from Johns Hopkins University, the Osler Housestaff Teaching Award, the Director's Teaching Award in Clinical Science, and the Advanced Clinical Research Award from the American Society of Clinical Oncology.Dr. Levis’ laboratory research focuses on the development of molecularly-targeted therapies for leukemia. He is actively involved in the pre-clinical and clinical development of small molecule inhibitors of protein kinases, including FLT3. The research involves studying the biochemical effects of these inhibitors on samples taken from leukemia patients, with the broad goal of identifying and validating novel molecular therapeutic targets in these hematopoietic malignancies. While Dr. Levis plays a key role in the pre-clinical development of these therapies, he is particularly interested in translating this research to the bedside of his patients by using correlative studies to incorporate these novel therapies into existing treatments. In addition to his work in both the clinic and the laboratory, Dr. Levis has also conducted talks, mentorship and teaching lectures, and published extensively in the top journals in his field, including Leukemia; Blood; and the New England Journal of Medicine.